The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Andrea Schub
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Research Funding - Amgen Research Munich GmbH
Virginie Nägele
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gerhard Zugmaier
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Christian Brandl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Youssef Hijazi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Max S. Topp
Consultant or Advisory Role - Amgen
Other Remuneration - Amgen
Peter Kufer
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andreas Wolf
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Matthias Klinger
Employment or Leadership Position - Amgen
Stock Ownership - Amgen